Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.32 |
| ▸ | CPB1 | P15086 | 6/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907438 | 0.89 | HTT (0.32) | CPB2CPB1HTTATMLMNA | |
| Hydrochloric Acid SCHEMBL28536680 | 0.79 | CPB2 (0.32) | CPB2CPB1 | |
| SCHEMBL4912275 | 0.78 | HTT (0.32) | HTTATMLMNAKMT2A | |
| Hydrochloric Acid SCHEMBL30280624 | 0.74 | CPB2 (0.34) | CPB2CPB1KMT2APOLBNPSR1 | |
| SCHEMBL24621004 | 0.71 | KDM4E (0.39) | CPB2CPB1KMT2A | |
| SCHEMBL31352606 | 0.68 | CYP2C9 (0.38) | CPB2TDP1 | |
| SCHEMBL30786466 | 0.67 | CPB2 (0.37) | CPB2CPB1 | |
| SCHEMBL2585024 | 0.67 | LMNA (0.34) | LMNAKMT2APOLBNPSR1TDP1 | |
| SCHEMBL7488160 | 0.66 | SLC7A5 (0.42) | CPB2CPB1 | |
| SCHEMBL8117391 | 0.66 | LNPEP (0.33) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | DAHMANN GEORG | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | CYP11B2, CYP3A43, CYP11B1 | CPB2 1197/4885CPB1 1655/4885HTT 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.